Conduit Retained Earnings from 2010 to 2024

CDTTW Stock   0.02  0.01  43.62%   
Conduit Pharmaceuticals Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings will likely drop to about -11.9 M in 2024. Retained Earnings is the cumulative amount of net income that Conduit Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2010-12-31
Previous Quarter
-11.3 M
Current Value
-11.9 M
Quarterly Volatility
2.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Conduit Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Conduit Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 159.5 K, Selling General Administrative of 4.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Conduit financial statements analysis is a perfect complement when working with Conduit Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Conduit Pharmaceuticals Correlation against competitors.
For more information on how to buy Conduit Stock please use our How to Invest in Conduit Pharmaceuticals guide.

Latest Conduit Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Conduit Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Conduit Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Conduit Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (11.3 M)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

Conduit Retained Earnings Regression Statistics

Arithmetic Mean(6,963,397)
Coefficient Of Variation(32.44)
Mean Deviation1,738,235
Median(5,877,000)
Standard Deviation2,258,643
Sample Variance5.1T
Range6M
R-Value(0.70)
Mean Square Error2.8T
R-Squared0.49
Significance0
Slope(353,127)
Total Sum of Squares71.4T

Conduit Retained Earnings History

2024-11.9 M
2023-11.3 M
2022-10.8 M

About Conduit Pharmaceuticals Financial Statements

Conduit Pharmaceuticals investors use historical fundamental indicators, such as Conduit Pharmaceuticals' Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Conduit Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Retained Earnings-11.3 M-11.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Conduit Stock Analysis

When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.